Provisional Agenda

---

Information Session (Public Consultation)

14 October 2024

Virtual

10:00-12:00 CET

1. Welcome and opening of the meeting
2. Role and Mandate of the WHO Expert Committee on Drug Dependence (ECDD)
3. WHO ECDD review procedure and processes
4. Presentations and statements from participants
Provisional Agenda

47th WHO EXPERT COMMITTEE ON DRUG DEPENDENCE
14-18 October 2024
Closed Session
Geneva, Switzerland

1) Procedural matters and updates
   a) Opening of meeting and welcoming remarks
   b) Procedural matters
      i) Confidentiality of undertaking
      ii) Declarations of Interest
      iii) Election of Chair, Co-Chair, and Rapporteur
      iv) Adoption of agenda

2) Updates on priorities from international agencies
   a) Briefings from international agencies on their work on the public health dimension of the world drug problem
   b) Updates on WHO ECDD meetings and recommendations
      i) Recommendations and outcomes of 46th ECDD
      ii) Recommendations from working group on substance surveillance

3) Informal update: ECDD review of coca leaf

---

1 There has been a notification from a Party to the 1961 or the 1971 Convention concerning the scheduling of a substance (Guidance on WHO review of psychoactive substances for international control, para 19(1)). In June 2023, WHO received an official notification from a Member State to conduct a critical review of coca leaf. Accordingly, in accordance with the Guidance on the WHO review of psychoactive substances for international control, a critical review of coca leaf is planned to be conducted in 2025 for the consideration of the Expert Committee on Drug Dependence. An informal update on preparations for such critical review will be presented at this meeting.
4) Critical reviews: Recommendations on the scope of international control

a) Synthetic cannabinoids
   i) hexahydrocannabinol (HHC)

b) Novel synthetic opioids
   i) N-pyrrolidino protonitazene (protonitazepyne)
   ii) N-pyrrolidino metonitazene (metonitazepyne)
   iii) Etonitazepipne (N-Piperidinyl etonitazene)
   iv) N-Desethyl-Isotonitazene

c) Dissociative-type substance
   i) 3-OH-PCP (3-Hydroxy-phencyclidine)

d) Cathinone/stimulant
   i) N-ethylheptedrone (Ephylon)

e) Medicine
   i) Carisoprodol

5) Finalisation of meeting report

---

2 Information was brought to WHO’s attention that these substances are clandestinely manufactured, of especially serious risk to public health and society, and of no recognised therapeutic use by any Party (Guidance on WHO review of psychoactive substances for international control, para 19(4)).

3 The pre-review of a substance has resulted in an Expert Committee recommendation for critical review (Guidance on WHO review of psychoactive substances for international control, para 19(3)).